CellPly

Executive Summary

CellPly is an Italian deep-tech company pioneering functional precision medicine with its VivaCyte platform, an automated nanoliter-scale system for high-resolution, single-cell drug response profiling. The technology aims to guide oncology treatment decisions and accelerate the development of next-generation cell therapies by providing real-time, functional data on drug efficacy at the single-cell level. By streamlining cell-based assays from discovery through quality control, CellPly offers significant value to biopharma and research institutes seeking to reduce drug development timelines and improve therapeutic outcomes. Founded in 2018 and based in Milan, CellPly operates in the diagnostics space with a focus on oncology and cell therapy. While the company has not disclosed funding or stage details, its innovative platform positions it well in the growing precision medicine market. Key near-term milestones include securing Series A funding, publishing clinical validation data, and establishing commercial partnerships. With a strong technology foundation and a clear value proposition, CellPly is poised for growth pending successful execution of its strategic initiatives.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round60% success
• Q2 2027Clinical Validation Study Publication50% success
• Q1 2027Biopharma Partnership for VivaCyte Platform40% success